Original source
Guidance / Q&A
How FDA is Implementing Landmark Cosmetics Legislation to Positively Impact Public Health (FDA Voices)
- Official date
- 2026-05-04
Unlock the official file
Business Impact stays free. Paid plans unlock the original source, official text, and Regulatory Details — plus Workbench and Verify credits.
Official source. FDA Voices — MoCRA implementation
Key points
- Narrative status of listing, AE, PFAS report, and remaining rules.
- Points back to the MoCRA landing page for primary documents.
Dates. Posted 4 May 2026 (FDA page date).
Verify in the official text. Which items are statute-already-in-force vs still proposed.
Open questions. Confirm any transitional stock rules and whether your exact INCI / product type is named. This desk brief is a prioritisation aid, not a legal determination.
What changed: FDA published an implementation narrative, not a new duty.
Who is affected: US RA leads briefing leadership.
Suggested next steps: Attach the post to the Q2 board pack; keep listing work on the live-duty list.
On 4 May 2026 FDA published a Voices post on MoCRA implementation, including the December 2025 PFAS report.
Owners can use it as a one-page status board for a board pack.
Do not change formulas from a Voices post. Change them from a Federal Register rule or a state act.
Official text
Extract from the official English instrument
Official English from the FDA Voices post “How FDA is Implementing Landmark Cosmetics Legislation…” (FDA page date 4 May 2026).
The post describes FDA’s implementation of MoCRA, including facility and product listing required of industry and the December 2025 PFAS report.
FDA: the PFAS report “included safety reviews of the 25 most commonly used PFAS in cosmetic products marketed in the United States,” identified from cosmetic product listings. “These PFAS-containing cosmetic products represent 0.41% of the total products listed as of August 2024 as reported in the Report on the Use of PFAS in Cosmetic Products and Associated Risks.”